low molecular weight – Page 6 – Communicable Diseases Research

Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study

Nutrition

Published on 2021-01-112022-10-31
Journal: Frontiers in Nutrition [Category] COVID-19,

Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors

Research article

Published on 2021-01-012022-10-05
Journal: Bioorganic & Medicinal Chemistry [Category] SARS, 신약개발,

Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up

90일 추적 관찰과 함께 COVID-19로 입원한 후 증상이 있는 영상 확인 정맥 혈전 색전증의 발생률

Article

Published on 2020-12-222022-09-11
Journal: Blood advances [Category] SARS, 바이오마커,

[키워드] 24 hour 24 hours Admission anticoagulation bleeding Care caution collected COVID-19 death discharge discharged event Follow-up heparin highlighting hospital Hospitalization indication invasive ventilation level of care low molecular weight low molecular weight heparin Lung imaging major bleeding majority medical record medical records National Noninvasive ventilation Observational data occurred on admission Patient patients presenting Prevention strategy Randomized controlled trial receive receiving reported retrospective risk standard thromboprophylaxis subsegmental symptomatic therapeutic anticoagulation Thromboprophylaxis thrombosis Treatment Venous Thromboembolism VTE ward were excluded
[DOI] 10.1182/bloodadvances.2020003349 PMC 바로가기 [Article Type] Article

A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

COVID-19 환자의 숙주 혈전 염증 반응 조절에 대한 무작위, 공개, 적응, 개념 증명 임상 시험: DAWn-Antico 연구

Randomized Controlled Trial

Published on 2020-12-092022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] Activation adaptive added Anakinra Aprotinin bradykinin cellular entry Clinical improvement clinical status clinical trial Coagulation Combination complications Contact country COVID-19 COVID-19 disease COVID-19 pandemic D-dimer defined develop Disease progression dose drug effective EU Clinical Trial EU Clinical Trials fibrinolysis heparin heparins high mortality hospitalized COVID-19 patients Host hyperinflammation ICU in vitro incidence Infection inflammatory parameters Inflammatory response information inhibitor inhibitory effect initial intensive care Intervention investigated Kallikrein local inflammatory response low molecular weight Low molecular weight heparins marker modulate modulation multicenter Open-label Ordinal Scale outcome pathophysiological pathway Patient Primary outcome Prognostic factor proof-of-concept clinical trial Randomized randomized clinical trial reached receptor receptor antagonist reduce regimen SARS-CoV-2 second wave severe COVID-19 severe COVID-19 disease shown standard thromboprophylaxis supplementary material the WHO Thromboinflammatory response thrombotic Thrombotic complications Thrombotic events Trial Trial registration vaccination Viral viral replication WHO ordinal scale
[DOI] 10.1186/s13063-020-04878-y PMC 바로가기 [Article Type] Randomized Controlled Trial

Treatment for COVID-19: An overview

Research article

Published on 2020-12-012022-10-05
Journal: European journal of pharmacology [Category] SARS, 치료법, 치료제,

[키워드] acute respiratory syndrome Angiogenesis Antirheumatic drugs Antiviral agents cause caused characteristic clinician Coronavirus disease 2019 Coronavirus-2 COVID-19 COVID-19 outbreak COVID-19 patients Cytokine storm death drug drugs Dyspnoea feature first stage heparins hyperimmune Hyperinflammatory immunoglobulins Infection Infectious disease Inflammation Inflammation inhibitors low molecular weight Low molecular weight heparins patients with moderate pharmacological treatment plasma researcher SARS-CoV-2 severe COVID-19 Stage Support the SARS-CoV-2 thrombosis Treatment upper respiratory tract variety Vascular damage widespread worsening
[DOI] 10.1016/j.ejphar.2020.173644 [Article Type] Research article

Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids

Pediatrics

Published on 2020-11-302022-10-31
Journal: Frontiers in Pediatrics [Category] COVID-19,

[키워드] addition Adolescent Adults affected Anakinra anti-inflammatory treatment biomarkers of inflammation bowel children clinical manifestation clinical response Combination coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critically ill CT scan Cytokine storm defined described disease Disease progression disorder Fever first symptom gastrointestinal involvement glucocorticoid had no hyperinflammation Inflammatory intensive care interleukin-1 less low molecular weight lung involvement management Methylprednisolone MIS-C Patient patients pediatric Pediatric patient PIMS-TS positive presenting Prognosis receptor respiratory SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR Standard dose syndrome treated WHO World Health Organization
[DOI] 10.3389/fped.2020.576912 PMC 바로가기 [Article Type] Pediatrics

Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study

Research Article

Published on 2020-11-162022-10-28
Journal: BMC Nephrology [Category] COVID-19, SARS,

[키워드] Abstract Acute kidney injury Administered administration AKI anticoagulation Care citrate cohort study collected data coronavirus disease Course COVID-19 COVID-19 patient Critical care Critically ill Critically ill patient dialysis effective Efficiency Emerging communicable diseases event Germany Health Hemodialysis high risk hypercoagulability intensive care unit LMWH low molecular weight maintain outcome Patient patients Prevent receiving reduce regimen renal replacement therapy Result RRT Safe SARS-CoV-2 significantly supplementary material sustained systemic anticoagulation the disease therapeutic Thromboembolic events Treatment unfractionated heparin was performed
[DOI] 10.1186/s12882-020-02150-8 PMC 바로가기 [Article Type] Research Article

D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review

정맥 혈전 색전증이 의심되는 COVID-19 환자의 D-이량체, 피브리노겐 및 IL-6: 내러티브 검토

Review

Published on 2020-11-132022-09-10
Journal: Vascular Health and Risk Management [Category] MERS, 바이오마커,

[키워드] activated acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus aPTT ARDS China Coagulation Coagulopathy coronavirus coronavirus disease Coronavirus disease 2019 cough COVID-19 COVID-19 patient COVID-19 patients critical COVID-19 patient critical COVID-19 patients Critically ill critically ill patients Cytokine storm D-dimer D-dimers Deep vein Deep vein thrombosis Degradation develop Disease progression Disseminated intravascular coagulation District DVT early diagnosis elevated Evidence evidence of Fever FIBRIN fibrin degradation products fibrinogen Fibrinogen levels global pandemic Health Organization heparin highlighting hyperactivity IL-6 include interleukin interleukin-6 intravascular coagulation Laboratory parameters lethargy LMWH low molecular weight low molecular weight heparin manifestation Mortality multiple organ failure narrative Organ failure Platelets Prognostic factor Prophylaxis prothrombin Prothrombin time Pulmonary embolism reducing respiratory respiratory distress review risk SARS-CoV-2 Seafood severe acute respiratory syndrome Coronavirus shown stages Suspected syndrome THROMBOPLASTIN Thromboprophylaxis thrombosis Thrombosis prophylaxis thrombotic thrombotic event Thrombotic events Treatment upper respiratory symptom upper respiratory symptoms Venous Thromboembolism VTE West WHO World Health Organization
[DOI] 10.2147/VHRM.S280962 PMC 바로가기 [Article Type] Review

Coronavirus-Associated Coagulopathy: Lessons From SARS-CoV1 and MERS-CoV for the Current SARS-CoV2 Pandemic

Internal Medicine

Published on 2020-11-032022-10-31
Journal: Cureus [Category] COVID-19,

[키워드] acute respiratory syndrome appear assist chest imaging clinical condition Clinical course clinician Coagulopathies Consensus Conservative management coronavirus coronavirus disease COVID-19 COVID-19-associated coagulopathy current Cytokine storm discharged home Effects elevated endothelial evaluate female Fever form Hospital stay hypercoagulability Hypothyroidism incidence Inflammation Inflammatory marker initial initiated intra-alveolar intubation left upper lobe lesson low molecular weight main pulmonary artery management manuscript mechanical ventilation MERS-CoV Middle East multifactorial nasopharyngeal nonproductive cough Pathogenesis pathophysiology Patient patients PCR test pro-inflammatory state Prophylactic recommendation remained respiratory syndrome coronavirus risk SARS virus SARS-CoV2 SARS-CoV2 infection SARS-CoV2- Seven stroke suggested systemic anticoagulation the timing therapeutic anticoagulation thrombosis Thrombotic complications tomography transferred while worsened
[DOI] 10.7759/cureus.11310 PMC 바로가기 [Article Type] Internal Medicine

Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease

Original Article

Published on 2020-10-232022-10-29
Journal: TH Open: Companion Journal to Thrombosis and Haemostasis [Category] COVID-19,

[키워드] acute respiratory distress anticoagulation apixaban Atrial fibrillation benefit bleeding bleeding event coagulation parameter Coagulation parameters Coagulopathy COVID-19 death Direct disease DOACs Efficacy evaluate evaluated follow-up period ICU ICU patient Ill incidence initiated intensive care LMWH low molecular weight major bleeding event material mechanical ventilation morbidity and mortality Mortality novel coronavirus disease obese oral anticoagulant Patient Prophylaxis remained renal dysfunction renal replacement therapy required respiratory Respiratory disease Result retrospective cohort study Safe Safety SARS-CoV-2 seeking severe COVID-19 severe COVID-19 disease study period subsequent syndrome thromboembolic disease Thromboembolic events thrombosis treated Treatment Trial unfractionated heparin Venous Thromboembolism VTE
[DOI] 10.1055/s-0040-1720962 PMC 바로가기 [Article Type] Original Article